EZH1 Inhibitors
1 drugsAbout EZH1
EZH1 (Enhancer of Zeste Homolog 1) is a histone methyltransferase involved in DNA packaging and gene regulation. It can maintain function even when EZH2 is inhibited, making it relevant for combination therapies. EZH1's activity impacts cancer development and progression through epigenetic regulation.
EZH1 is targeted to restore normal gene expression patterns and potentially halt tumor growth. There is currently no genetic evidence directly linking EZH1 mutations to specific diseases. Modulating EZH1 activity could have therapeutic benefits in certain cancers.
EZH1 is targeted by one FDA-approved drug, TAZVERIK, a small molecule developed by EPIZYME INC for oncology indications. TAZVERIK was first approved in 2020.
Top EZH1 Drugs
EPIZYME INC is the only company with an approved drug targeting EZH1.
The market is not yet saturated, presenting an opportunity for new entrants with differentiated EZH1 inhibitors.
EZH1 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets EZH1, using small molecule modality.
Explore alternative modalities like PROTACs or antibodies to differentiate from existing therapies.
EZH1 Clinical Trials 49 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on EZH1. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 29 | 6 | 11 | 12 | 35% |
| Phase 2 | 19 | 7 | 5 | 6 | 58% |
| Phase 3 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
EZH1 Drug Approval Timeline (2020 - 2020)
The first and most recent drug approval for EZH1 was TAZVERIK in 2020.
The recent approval suggests renewed interest, but further approvals are needed to confirm sustained therapeutic value.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 26 (6 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on EZH1. A trial counts if an approved drug acting on EZH1 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.